adalimumab-afzb (Abrilada) vs infliximab-axxq (Avsola)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Rheumatoid Arthritis

Shared mechanism: TNF-alpha · full Rheumatoid Arthritis pipeline

adalimumab-afzb (Abrilada)

Marketed by Pfizer

Approved in Rheumatoid Arthritismonoclonal antibody
Reliable signal

NCT02480153 · Phase 3 · completed

This was a randomized, quadruple-blind, active-controlled Phase 3 trial in 597 patients comparing PF-06410293 with adalimumab-EU on a hard clinical endpoint: ACR20 response at Week 12. The primary equivalence analysis succeeded, with the 95% confidence interval for the response rate difference falling entirely within the prespecified -14% to +14% margin (observed difference -2.98%, 95% CI -10.38% to 4.44%). The large sample size, blinding, active comparator, and met primary endpoint together provide strong evidence of equivalent efficacy.

Reported efficacy

Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12: Period 1: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12: Period 1 (Week 12): Period 1: PF-06410293 68.35% vs Period 1: Adalimumab-EU 71.33% (met)

Result source: NCT02480153

infliximab-axxq (Avsola)

Marketed by Amgen

Approved in Rheumatoid Arthritismonoclonal antibody
Partial signal

NCT02937701 · Phase 3 · completed

The single primary endpoint was ACR20 response at week 22, tested for equivalence with a margin of -15% to 15%. The prespecified analysis gave a response difference of 9.37% with a 90% confidence interval of 2.67% to 15.96%, so the upper bound passed the margin and equivalence was not shown, while non-inferiority held; only a post hoc covariate-adjusted analysis fell inside the margin. The primary result is therefore unclear. Figures are from the ClinicalTrials.gov posted results.

Reported efficacy

Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 22 (Baseline and week 22): Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 22 (Baseline and week 22): ABP 710 68.1 percentage of participants (95% CI 62.63 to 73.57) | Infliximab 59.1 percentage of participants (95% CI 53.37 to 64.91) (unclear)

Result source: NCT02937701

Results for Rheumatoid Arthritis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointadalimumab-afzb (Abrilada)infliximab-axxq (Avsola)
ACR2068.3% vs 71.3%vs Adalimumab-EUwk 12 · n 297NCT02480153
11 other results
  • 82.7% vs 79.3% wk 52 · n 283 · Phase 3 · secondary NCT02480153
  • 82.3% vs 78.5% wk 44 · n 283 · Phase 3 · secondary NCT02480153
  • 83.4% vs 77.8% wk 36 · n 283 · Phase 3 · secondary NCT02480153
  • 86.6% vs 82.2% wk 30 · n 283 · Phase 3 · secondary NCT02480153
  • 83.5% vs 78% wk 26 · n 297 · Phase 3 · secondary NCT02480153
  • 86.6% vs 84.4% wk 26 · n 283 · Phase 3 · secondary NCT02480153
  • 78.1% vs 73.7% wk 18 · n 297 · Phase 3 · secondary NCT02480153
  • 69.4% vs 68% wk 8 · n 297 · Phase 3 · secondary NCT02480153
  • 61.3% vs 59.7% wk 6 · n 297 · Phase 3 · secondary NCT02480153
  • 51.9% vs 52.3% wk 4 · n 297 · Phase 3 · secondary NCT02480153
  • 31.3% vs 32% wk 2 · n 297 · Phase 3 · secondary NCT02480153
—Not reported
ACR5062.9% vs 55.6%vs Adalimumab-EUwk 52 · n 283NCT02480153
11 other results
  • 64.3% vs 49.6% wk 44 · n 283 · Phase 3 · secondary NCT02480153
  • 61.1% vs 51.9% wk 36 · n 283 · Phase 3 · secondary NCT02480153
  • 59.7% vs 49.6% wk 30 · n 283 · Phase 3 · secondary NCT02480153
  • 59.6% vs 54.7% wk 26 · n 297 · Phase 3 · secondary NCT02480153
  • 61.8% vs 56.3% wk 26 · n 283 · Phase 3 · secondary NCT02480153
  • 45.1% vs 47% wk 18 · n 297 · Phase 3 · secondary NCT02480153
  • 39.7% vs 39.7% wk 12 · n 297 · Phase 3 · secondary NCT02480153
  • 34% vs 33.3% wk 8 · n 297 · Phase 3 · secondary NCT02480153
  • 27.6% vs 27.3% wk 6 · n 297 · Phase 3 · secondary NCT02480153
  • 17.8% vs 14.3% wk 4 · n 297 · Phase 3 · secondary NCT02480153
  • 8.4% vs 6% wk 2 · n 297 · Phase 3 · secondary NCT02480153
—Not reported
ACR7036.4% vs 31.9%vs Adalimumab-EUwk 52 · n 283NCT02480153
11 other results
  • 38.5% vs 32.6% wk 44 · n 283 · Phase 3 · secondary NCT02480153
  • 36% vs 26.7% wk 36 · n 283 · Phase 3 · secondary NCT02480153
  • 33.9% vs 30.4% wk 30 · n 283 · Phase 3 · secondary NCT02480153
  • 29.6% vs 31% wk 26 · n 297 · Phase 3 · secondary NCT02480153
  • 31.1% vs 30.4% wk 26 · n 283 · Phase 3 · secondary NCT02480153
  • 21.5% vs 22% wk 18 · n 297 · Phase 3 · secondary NCT02480153
  • 16.5% vs 19% wk 12 · n 297 · Phase 3 · secondary NCT02480153
  • 12.5% vs 11.7% wk 8 · n 297 · Phase 3 · secondary NCT02480153
  • 8.1% vs 8.7% wk 6 · n 297 · Phase 3 · secondary NCT02480153
  • 3.7% vs 3.7% wk 4 · n 297 · Phase 3 · secondary NCT02480153
  • 0.7% vs 2% wk 2 · n 297 · Phase 3 · secondary NCT02480153
—Not reported
DAS28-CRP remission—Not reported—Not reported
HAQ-DI, change-0.7 vs -0.7vs Adalimumab-EUwk 52 · n 283NCT02480153
11 other results
  • -0.7 vs -0.7 wk 44 · n 283 · Phase 3 · secondary NCT02480153
  • -0.7 vs -0.7 wk 36 · n 283 · Phase 3 · secondary NCT02480153
  • -0.7 vs -0.7 wk 30 · n 283 · Phase 3 · secondary NCT02480153
  • -0.7 vs -0.7 wk 26 · n 297 · Phase 3 · secondary NCT02480153
  • -0.7 vs -0.7 wk 26 · n 283 · Phase 3 · secondary NCT02480153
  • -0.6 vs -0.6 wk 18 · n 297 · Phase 3 · secondary NCT02480153
  • -0.5 vs -0.5 wk 12 · n 297 · Phase 3 · secondary NCT02480153
  • -0.5 vs -0.5 wk 8 · n 297 · Phase 3 · secondary NCT02480153
  • -0.4 vs -0.5 wk 6 · n 297 · Phase 3 · secondary NCT02480153
  • -0.3 vs -0.4 wk 4 · n 297 · Phase 3 · secondary NCT02480153
  • -0.3 vs -0.3 wk 2 · n 297 · Phase 3 · secondary NCT02480153
—Not reported
Modified Sharp score, change—Not reported—Not reported

ACR20

adalimumab-afzb (Abrilada)
68.3% vs 71.3%vs Adalimumab-EUwk 12 · n 297NCT02480153
11 other results
  • 82.7% vs 79.3% wk 52 · n 283 · Phase 3 · secondary NCT02480153
  • 82.3% vs 78.5% wk 44 · n 283 · Phase 3 · secondary NCT02480153
  • 83.4% vs 77.8% wk 36 · n 283 · Phase 3 · secondary NCT02480153
  • 86.6% vs 82.2% wk 30 · n 283 · Phase 3 · secondary NCT02480153
  • 83.5% vs 78% wk 26 · n 297 · Phase 3 · secondary NCT02480153
  • 86.6% vs 84.4% wk 26 · n 283 · Phase 3 · secondary NCT02480153
  • 78.1% vs 73.7% wk 18 · n 297 · Phase 3 · secondary NCT02480153
  • 69.4% vs 68% wk 8 · n 297 · Phase 3 · secondary NCT02480153
  • 61.3% vs 59.7% wk 6 · n 297 · Phase 3 · secondary NCT02480153
  • 51.9% vs 52.3% wk 4 · n 297 · Phase 3 · secondary NCT02480153
  • 31.3% vs 32% wk 2 · n 297 · Phase 3 · secondary NCT02480153
infliximab-axxq (Avsola)
—Not reported

ACR50

adalimumab-afzb (Abrilada)
62.9% vs 55.6%vs Adalimumab-EUwk 52 · n 283NCT02480153
11 other results
  • 64.3% vs 49.6% wk 44 · n 283 · Phase 3 · secondary NCT02480153
  • 61.1% vs 51.9% wk 36 · n 283 · Phase 3 · secondary NCT02480153
  • 59.7% vs 49.6% wk 30 · n 283 · Phase 3 · secondary NCT02480153
  • 59.6% vs 54.7% wk 26 · n 297 · Phase 3 · secondary NCT02480153
  • 61.8% vs 56.3% wk 26 · n 283 · Phase 3 · secondary NCT02480153
  • 45.1% vs 47% wk 18 · n 297 · Phase 3 · secondary NCT02480153
  • 39.7% vs 39.7% wk 12 · n 297 · Phase 3 · secondary NCT02480153
  • 34% vs 33.3% wk 8 · n 297 · Phase 3 · secondary NCT02480153
  • 27.6% vs 27.3% wk 6 · n 297 · Phase 3 · secondary NCT02480153
  • 17.8% vs 14.3% wk 4 · n 297 · Phase 3 · secondary NCT02480153
  • 8.4% vs 6% wk 2 · n 297 · Phase 3 · secondary NCT02480153
infliximab-axxq (Avsola)
—Not reported

ACR70

adalimumab-afzb (Abrilada)
36.4% vs 31.9%vs Adalimumab-EUwk 52 · n 283NCT02480153
11 other results
  • 38.5% vs 32.6% wk 44 · n 283 · Phase 3 · secondary NCT02480153
  • 36% vs 26.7% wk 36 · n 283 · Phase 3 · secondary NCT02480153
  • 33.9% vs 30.4% wk 30 · n 283 · Phase 3 · secondary NCT02480153
  • 29.6% vs 31% wk 26 · n 297 · Phase 3 · secondary NCT02480153
  • 31.1% vs 30.4% wk 26 · n 283 · Phase 3 · secondary NCT02480153
  • 21.5% vs 22% wk 18 · n 297 · Phase 3 · secondary NCT02480153
  • 16.5% vs 19% wk 12 · n 297 · Phase 3 · secondary NCT02480153
  • 12.5% vs 11.7% wk 8 · n 297 · Phase 3 · secondary NCT02480153
  • 8.1% vs 8.7% wk 6 · n 297 · Phase 3 · secondary NCT02480153
  • 3.7% vs 3.7% wk 4 · n 297 · Phase 3 · secondary NCT02480153
  • 0.7% vs 2% wk 2 · n 297 · Phase 3 · secondary NCT02480153
infliximab-axxq (Avsola)
—Not reported

DAS28-CRP remission

adalimumab-afzb (Abrilada)
—Not reported
infliximab-axxq (Avsola)
—Not reported

HAQ-DI, change

adalimumab-afzb (Abrilada)
-0.7 vs -0.7vs Adalimumab-EUwk 52 · n 283NCT02480153
11 other results
  • -0.7 vs -0.7 wk 44 · n 283 · Phase 3 · secondary NCT02480153
  • -0.7 vs -0.7 wk 36 · n 283 · Phase 3 · secondary NCT02480153
  • -0.7 vs -0.7 wk 30 · n 283 · Phase 3 · secondary NCT02480153
  • -0.7 vs -0.7 wk 26 · n 297 · Phase 3 · secondary NCT02480153
  • -0.7 vs -0.7 wk 26 · n 283 · Phase 3 · secondary NCT02480153
  • -0.6 vs -0.6 wk 18 · n 297 · Phase 3 · secondary NCT02480153
  • -0.5 vs -0.5 wk 12 · n 297 · Phase 3 · secondary NCT02480153
  • -0.5 vs -0.5 wk 8 · n 297 · Phase 3 · secondary NCT02480153
  • -0.4 vs -0.5 wk 6 · n 297 · Phase 3 · secondary NCT02480153
  • -0.3 vs -0.4 wk 4 · n 297 · Phase 3 · secondary NCT02480153
  • -0.3 vs -0.3 wk 2 · n 297 · Phase 3 · secondary NCT02480153
infliximab-axxq (Avsola)
—Not reported

Modified Sharp score, change

adalimumab-afzb (Abrilada)
—Not reported
infliximab-axxq (Avsola)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

infliximab-axxq (Avsola): registry results are on file for Rheumatoid Arthritis, but their comparison mappings are not yet available.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. adalimumab-afzb (Abrilada): 2 of 4 rows · infliximab-axxq (Avsola): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricadalimumab-afzb (Abrilada)
Dropout rate
—Period 1: PF-06410293a
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 3 more results
—Period 2: PF-06410293/PF-06410293
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
—Period 3: PF-06410293/PF-06410293/
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
—
NCT04230213 · Phase 3
Discontinued due to AEs
—Period 1: PF-06410293a
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 3 more results
—Period 2: PF-06410293/PF-06410293
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
—Period 3: PF-06410293/PF-06410293/
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
—
NCT04230213 · Phase 3
Serious AEs
4%Period 1: PF-06410293a
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 3 more results
1.4%Period 2: PF-06410293/PF-06410293
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
3.5%Period 3: PF-06410293/PF-06410293/
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
1.4%
NCT04230213 · Phase 3
Most frequent reported AEs
a
viral upper respiratory tract infection 7.1%
rheumatoid arthritis 1.7%
nasopharyngitis 0%
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 3 more results
viral upper respiratory tract infection 5.3%
rheumatoid arthritis 1.4%
nasopharyngitis 0.4%
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
nasopharyngitis 5%
rheumatoid arthritis 4.7%
viral upper respiratory tract infection 0.4%
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
sars-cov-2 test positive 8.5%
covid-19 7.5%
erythema 2.8%
NCT04230213 · Phase 3

Notes

  1. aPopulation comparability has not been reviewed for 1 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

adalimumab-afzb (Abrilada)

ACR20 68.35% (n=297) vs 71.33% (n=300) Adalimumab-EU @ 12wk
responder rate · % of participants
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 11 more results
31.3% (n=297) vs 32% (n=300) Adalimumab-EU @ 2wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 93 Participants as posted
51.9% (n=297) vs 52.3% (n=300) Adalimumab-EU @ 4wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 154 Participants as posted
61.3% (n=297) vs 59.7% (n=300) Adalimumab-EU @ 6wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 182 Participants as posted
69.4% (n=297) vs 68% (n=300) Adalimumab-EU @ 8wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 206 Participants as posted
78.1% (n=297) vs 73.7% (n=300) Adalimumab-EU @ 18wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 232 Participants as posted
83.5% (n=297) vs 78% (n=300) Adalimumab-EU @ 26wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 248 Participants as posted
86.6% (n=283) vs 84.4% (n=135) Adalimumab-EU @ 26wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 245 Participants as posted
86.6% (n=283) vs 82.2% (n=135) Adalimumab-EU @ 30wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 245 Participants as posted
83.4% (n=283) vs 77.8% (n=135) Adalimumab-EU @ 36wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 236 Participants as posted
82.3% (n=283) vs 78.5% (n=135) Adalimumab-EU @ 44wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 233 Participants as posted
82.7% (n=283) vs 79.3% (n=135) Adalimumab-EU @ 52wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 234 Participants as posted
ACR20 88.4% (n=259) @ 52wk
responder rate · % of participants
No placebo or comparator arm
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 229 Participants as posted
show 4 more results
88.8% (n=259) @ 56wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 230 Participants as posted
87.3% (n=259) @ 66wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 226 Participants as posted
84.6% (n=259) @ 76wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 219 Participants as posted
83.4% (n=259) @ 78wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 216 Participants as posted
ACR50 8.4% (n=297) vs 6% (n=300) Adalimumab-EU @ 2wk
responder rate · % of participants
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 25 Participants as posted
show 11 more results
17.8% (n=297) vs 14.3% (n=300) Adalimumab-EU @ 4wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 53 Participants as posted
27.6% (n=297) vs 27.3% (n=300) Adalimumab-EU @ 6wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 82 Participants as posted
34% (n=297) vs 33.3% (n=300) Adalimumab-EU @ 8wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 101 Participants as posted
39.7% (n=297) vs 39.7% (n=300) Adalimumab-EU @ 12wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 118 Participants as posted
45.1% (n=297) vs 47% (n=300) Adalimumab-EU @ 18wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 134 Participants as posted
59.6% (n=297) vs 54.7% (n=300) Adalimumab-EU @ 26wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 177 Participants as posted
61.8% (n=283) vs 56.3% (n=135) Adalimumab-EU @ 26wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 175 Participants as posted
59.7% (n=283) vs 49.6% (n=135) Adalimumab-EU @ 30wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 169 Participants as posted
61.1% (n=283) vs 51.9% (n=135) Adalimumab-EU @ 36wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 173 Participants as posted
64.3% (n=283) vs 49.6% (n=135) Adalimumab-EU @ 44wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 182 Participants as posted
62.9% (n=283) vs 55.6% (n=135) Adalimumab-EU @ 52wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 178 Participants as posted
ACR50 68.3% (n=259) @ 52wk
responder rate · % of participants
No placebo or comparator arm
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 177 Participants as posted
show 4 more results
67.6% (n=259) @ 56wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 175 Participants as posted
68.3% (n=259) @ 66wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 177 Participants as posted
69.1% (n=259) @ 76wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 179 Participants as posted
71.4% (n=259) @ 78wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 185 Participants as posted
ACR70 0.7% (n=297) vs 2% (n=300) Adalimumab-EU @ 2wk
responder rate · % of participants
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 2 Participants as posted
show 11 more results
3.7% (n=297) vs 3.7% (n=300) Adalimumab-EU @ 4wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 11 Participants as posted
8.1% (n=297) vs 8.7% (n=300) Adalimumab-EU @ 6wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 24 Participants as posted
12.5% (n=297) vs 11.7% (n=300) Adalimumab-EU @ 8wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 37 Participants as posted
16.5% (n=297) vs 19% (n=300) Adalimumab-EU @ 12wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 49 Participants as posted
21.5% (n=297) vs 22% (n=300) Adalimumab-EU @ 18wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 64 Participants as posted
29.6% (n=297) vs 31% (n=300) Adalimumab-EU @ 26wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 88 Participants as posted
31.1% (n=283) vs 30.4% (n=135) Adalimumab-EU @ 26wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 88 Participants as posted
33.9% (n=283) vs 30.4% (n=135) Adalimumab-EU @ 30wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 96 Participants as posted
36% (n=283) vs 26.7% (n=135) Adalimumab-EU @ 36wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 102 Participants as posted
38.5% (n=283) vs 32.6% (n=135) Adalimumab-EU @ 44wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 109 Participants as posted
36.4% (n=283) vs 31.9% (n=135) Adalimumab-EU @ 52wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 103 Participants as posted
ACR70 39.8% (n=259) @ 52wk
responder rate · % of participants
No placebo or comparator arm
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 103 Participants as posted
show 4 more results
39% (n=259) @ 56wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 101 Participants as posted
43.2% (n=259) @ 66wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 112 Participants as posted
45.6% (n=259) @ 76wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 118 Participants as posted
49.4% (n=259) @ 78wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 128 Participants as posted
Tender Joint Count -7.5 vs -7.1 Adalimumab-EU joints @ 2wk
absolute change · joints
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 11 more results
-10.2 vs -10.7 Adalimumab-EU joints @ 4wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-12.8 vs -13.1 Adalimumab-EU joints @ 6wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-14.2 vs -15.2 Adalimumab-EU joints @ 8wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-15.4 vs -16.1 Adalimumab-EU joints @ 12wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-16.8 vs -17.3 Adalimumab-EU joints @ 18wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-18.4 vs -19.2 Adalimumab-EU joints @ 26wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-18.4 vs -20.1 Adalimumab-EU joints @ 26wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-19 vs -19.5 Adalimumab-EU joints @ 30wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-18.7 vs -20.1 Adalimumab-EU joints @ 36wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-19.4 vs -21.5 Adalimumab-EU joints @ 44wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-18.9 vs -21 Adalimumab-EU joints @ 52wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
Tender Joint Count -19.3 joints @ 52wk
absolute change · joints
No placebo or comparator arm
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 4 more results
-19.4 joints @ 56wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-19.5 joints @ 66wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-20.6 joints @ 76wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-20.5 joints @ 78wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
Swollen Joint Count -5.7 vs -6.1 Adalimumab-EU joints @ 2wk
absolute change · joints
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 11 more results
-7.7 vs -8.2 Adalimumab-EU joints @ 4wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-9 vs -9.7 Adalimumab-EU joints @ 6wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-9.8 vs -11 Adalimumab-EU joints @ 8wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-10.4 vs -11.8 Adalimumab-EU joints @ 12wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-11.3 vs -13 Adalimumab-EU joints @ 18wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-12.2 vs -13.6 Adalimumab-EU joints @ 26wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-12.2 vs -13.6 Adalimumab-EU joints @ 26wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-12.3 vs -13.3 Adalimumab-EU joints @ 30wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-12.4 vs -14.2 Adalimumab-EU joints @ 36wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-12.8 vs -14.7 Adalimumab-EU joints @ 44wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-12.6 vs -14.2 Adalimumab-EU joints @ 52wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
Swollen Joint Count -12.8 joints @ 52wk
absolute change · joints
No placebo or comparator arm
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 4 more results
-12.9 joints @ 56wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-13 joints @ 66wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-13.3 joints @ 76wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-13.4 joints @ 78wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
Physician Global Assessment -20.7 vs -20.5 Adalimumab-EU score @ 2wk
absolute change · score
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 11 more results
-28.9 vs -29 Adalimumab-EU score @ 4wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-32.6 vs -33 Adalimumab-EU score @ 6wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-35.6 vs -37.1 Adalimumab-EU score @ 8wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-40.4 vs -40.5 Adalimumab-EU score @ 12wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-44.2 vs -44.2 Adalimumab-EU score @ 18wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-47.2 vs -46.5 Adalimumab-EU score @ 26wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-47.7 vs -45.5 Adalimumab-EU score @ 26wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-47.9 vs -46.5 Adalimumab-EU score @ 30wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-47.3 vs -45.4 Adalimumab-EU score @ 36wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-49.1 vs -46.9 Adalimumab-EU score @ 44wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-47.9 vs -48.4 Adalimumab-EU score @ 52wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
Physician Global Assessment -48.9 score @ 52wk
absolute change · score
No placebo or comparator arm
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 4 more results
-50.5 score @ 56wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-49.4 score @ 66wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-50.9 score @ 76wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-52.3 score @ 78wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3

+ 46 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: adalimumab-afzb (Abrilada)'s landscape · infliximab-axxq (Avsola)'s landscape